Twelve Bio

About:

Twelve Bio is a developer of CRISPR-Cas12a diagnostic technology can detect and change any DNA sequence.

Description:

Twelve Bio is a developer of CRISPR-Cas12a diagnostic technology can detect and change any DNA sequence. CRISPR-Cas12a is an RNA-protein molecule that allow us to identify and modify specific DNA sequences. The RNA works like a search engine that identifies the specific DNA sequence and the protein is the biological scissor that cuts it.

Total Funding Amount:

$519000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Copenhagen, Hovedstaden, Denmark

Founded Date:

2019-01-01

Contact Email:

hello(AT)twelve.bio

Founders:

Guillermo Montoya, Stefano Stella

Number of Employees:

1-10

Last Funding Date:

2019-11-01

IPO Status:

Private

Industries: